

**Jubilant Life Sciences Switzerland AG**  
**Balance Sheet as at 31 March 2017**

	Notes	CHF	(₹ in thousand)	CHF	(₹ in thousand)	CHF	(₹ in thousand)
		As at 31-Mar-17		As at 31-Mar-16		As at 1-Apr-15	
<b>ASSETS</b>							
<b>Current assets</b>							
<b>Financial assets</b>							
i. Cash and cash equivalents	1	-	-	-	-	29,711	1,909
ii. Other financial assets	2	3,099	201	5,142	355	-	-
<b>Total current assets</b>		<b>3,099</b>	<b>201</b>	<b>5,142</b>	<b>355</b>	<b>29,711</b>	<b>1,909</b>
<b>Total assets</b>		<b>3,099</b>	<b>201</b>	<b>5,142</b>	<b>355</b>	<b>29,711</b>	<b>1,909</b>
<b>EQUITY AND LIABILITIES</b>							
<b>Equity</b>							
Equity share capital	3(a)	100,000	4,697	100,000	4,697	100,000	4,697
Other equity	3(b)	(120,085)	(5,999)	(94,858)	(4,342)	(87,336)	(3,883)
<b>Total equity</b>		<b>(20,085)</b>	<b>(1,302)</b>	<b>5,142</b>	<b>355</b>	<b>12,664</b>	<b>814</b>
<b>LIABILITIES</b>							
<b>Current liabilities</b>							
<b>Financial liabilities</b>							
ii. Trade payables	4	23,184	1,503	-	-	17,047	1,095
<b>Total current liabilities</b>		<b>23,184</b>	<b>1,503</b>	<b>-</b>	<b>-</b>	<b>17,047</b>	<b>1,095</b>
<b>Total liabilities</b>		<b>23,184</b>	<b>1,503</b>	<b>-</b>	<b>-</b>	<b>17,047</b>	<b>1,095</b>
<b>Total equity and liabilities</b>		<b>3,099</b>	<b>201</b>	<b>5,142</b>	<b>355</b>	<b>29,711</b>	<b>1,909</b>

**PRAKASH C BISHT**  
**CFO (LSI) & Sr. VP (Group Accounts)**

Place: Noida  
Date: 22 April, 2017

Jubilant Life Sciences Switzerland AG  
Statement of Profit and Loss for the year ended 31 March 2017

		CHF	(₹ in thousand)	CHF	(₹ in thousand)
	Notes	For the year ended 31-Mar-17		For the year ended 31-Mar-16	
<b>Revenue</b>					
Other income		-	-	-	-
<b>Total income</b>		-	-	-	-
<b>Expenses</b>					
Other expenses	5	25,227	1,707	7,522	505
<b>Total expenses</b>		<b>25,227</b>	<b>1,707</b>	<b>7,522</b>	<b>505</b>
<b>Loss before tax</b>		<b>(25,227)</b>	<b>(1,707)</b>	<b>(7,522)</b>	<b>(505)</b>
<b>Tax expense</b>					
- Current tax		-	-	-	-
- Deferred tax charge		-	-	-	-
<b>Total tax expense</b>		<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Loss for the year</b>		<b>(25,227)</b>	<b>(1,707)</b>	<b>(7,522)</b>	<b>(505)</b>
<b>Other comprehensive income</b>					
Items that will be reclassified to profit or loss					
Exchange differences on translation of foreign operations		-	50	-	46
<b>Other comprehensive income for the year, net of tax</b>		<b>-</b>	<b>50</b>	<b>-</b>	<b>46</b>
<b>Total comprehensive income for the year</b>		<b>(25,227)</b>	<b>(1,657)</b>	<b>(7,522)</b>	<b>(459)</b>

**PRAKASH C BISHT**  
CFO (LSI) & Sr. VP (Group Accounts)

Place: Noida  
Date: 22 April, 2017

**Jubilant Life Sciences Switzerland AG**  
**Statement of Cash Flows for the year ended 31 March 2017**

	CHF	(₹ in thousand)	CHF	(₹ in thousand)
	For the year ended 31-Mar-17		For the year ended 31-Mar-16	
<b>A. Cash flow from operating activities</b>				
Net loss before tax	(25,227)	(1,707)	(7,522)	(505)
Adjustments :				
Irrecoverable advances written off	-	-	(3,404)	(228)
	-	-	(3,404)	(228)
<b>Operating cash flow before working capital changes</b>	<b>(25,227)</b>	<b>(1,707)</b>	<b>(10,926)</b>	<b>(733)</b>
Decrease/(increase) in trade receivable and other financial assets	2,043	139	(5,142)	(345)
Increase/(decrease) in trade payables, provisions and other liabilities	23,184	1,573	(13,643)	(915)
<b>Cash generated from operations</b>	<b>-</b>	<b>5</b>	<b>(29,711)</b>	<b>(1,993)</b>
Income tax and wealth tax paid (net of refund)	-	-	-	-
<b>Net cash generated from operating activities</b>	<b>-</b>	<b>5</b>	<b>(29,711)</b>	<b>(1,993)</b>
<b>B. Cash flow from investing activities</b>				
Net cash used in investing activities	-	-	-	-
<b>C. Cash flow from financing activities</b>				
Net cash used in financing activities	-	-	-	-
<b>D. Effect of exchange rate changes</b>	<b>-</b>	<b>(5)</b>	<b>-</b>	<b>84</b>
<b>Net decrease in cash and cash equivalents (A+B+C+D)</b>	<b>-</b>	<b>-</b>	<b>(29,711)</b>	<b>(1,909)</b>
Add: cash and cash equivalents at the beginning of year	-	-	29,711	1,909
<b>Cash and cash equivalents at the end of the year</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>

**PRAKASH C BISHT**  
**CFO (LSI) & Sr. VP (Group Accounts)**

Place: Noida  
Date: 22 April, 2017

**Jubilant Life Sciences Switzerland AG**

Notes to the financial statements for the year ended 31 March 2017

**1. Cash and cash equivalents**

	CHF	(₹ in thousand)	CHF	(₹ in thousand)	CHF	(₹ in thousand)
	As at		As at		As at	
	31 March 2017		31 March 2016		01 April 2015	
<b>Balances with banks</b>						
- in current accounts	-	-	-	-	29,711	1,909
<b>Total cash and cash equivalents</b>	-	-	-	-	<b>29,711</b>	<b>1,909</b>

**2. Other financial assets**

	CHF	(₹ in thousand)	CHF	(₹ in thousand)	CHF	(₹ in thousand)
	As at		As at		As at	
	31 March 2017		31 March 2016		01 April 2015	
	Current		Current		Current	
Advances recoverable from related parties	3,099	201	5,142	355	-	-
<b>Total loans</b>	<b>3,099</b>	<b>201</b>	<b>5,142</b>	<b>355</b>	<b>-</b>	<b>-</b>



Jubilant Life Sciences Switzerland AG  
Notes to the financial statements for the year ended 31 March 2017

4. Trade payables

	CHF	(₹ in thousand)	CHF	(₹ in thousand)	CHF	(₹ in thousand)
	As at		As at		As at	
	31 March 2017		31 March 2016		01 April 2015	
Current						
Trade payables	23,184	1,503	-	-	17,047	1,095
<b>Total trade payables</b>	<b>23,184</b>	<b>1,503</b>	<b>-</b>	<b>-</b>	<b>17,047</b>	<b>1,095</b>

**Jubilant Life Sciences Switzerland AG**

Notes to the financial statements for the year ended 31 March 2017

**5. Other expenses**

Particulars	CHF (₹ in thousand)		CHF (₹ in thousand)	
	For the year ended		For the year ended	
	31 March 2017		31 March 2016	
Rent	1,620	110	1,215	81
Legal and professional fees	23,286	1,575	7,231	489
Bank charges	-	-	2,480	166
Irrecoverable advances written off	-	-	(3,404)	(231)
Foreign Exchange Gain/Loss	321	22	-	-
<b>Total other expenses</b>	<b>25,227</b>	<b>1,707</b>	<b>7,522</b>	<b>505</b>